Active
A Phase IIb/III multicenter study comparing the efficacy of trabectedin administered as a 3-hour or 24-hour infusion to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma
Type of Sarcoma:
advanced or metastatic untreated soft tissue sarcoma
Drug:
trabectedin infused to doxorubicin
Accrual Status:
Open, Not Accruing
Overall Study Principal Investigator:
James E. Butrynski, MD
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute